RPA2, a subunit of the heterotrimeric replication protein A (RPA) complex, is overexpressed in various cancers. In this study, we showed a significant RPA2 upregulation in breast cancer tissues and cell lines. Ectopic expression of RPA2 in MCF7 and MDA-MB-231 cells promoted cell proliferation, adhesion, migration and invasion, and induced epithelial-mesenchymal transition (EMT) of MCF7 cells. Ablation of RPA2 in MDA-MB-231 cells induced apoptosis and suppressed colony formation, EMT and invasion. Binding assays indicated that menin, the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene product, interacted with RPA2. Ectopic expression of RPA2 inhibited the formation of the menin-NK-κB p65 complex and repressed the inhibitory effect of menin on expression of NF-κB-regulated genes that contribute to tumor progression. Conversely, knockdown of RPA2 promoted formation of the menin-p65 complex and repressed the expression of NF-κB-mediated genes. RPA2 expression was induced via an E2F1-dependent mechanism in MCF7 and MDA-MB-231 cells treated with NF-κB activators, TNF-alpha or lipopolysaccharide (LPS). These results suggested that RPA2-dependent tumorigenicity was mediated via enhancement of NF-κB activity by relieving the antagonistic function of menin on NF-κB-regulated transcription in breast cancer cells.
Introduction
Replication protein A (RPA) is a single-stranded DNA (ssDNA)-binding protein which plays a major role in DNA replication, DNA repair, recombination, cell cycle and DNA damage checkpoints (1) . The RPA heterotrimeric protein comprises the RPA1 (70 kDa), RPA2 (32 kDa) and RPA3 (14 kDa) subunits (2) . RPA1 binds ssDNA with high affinity and its activity is regulated by changes in the pattern of RPA2 phosphorylation. RPA2 is phosphorylated during the G/S transition, G2 and M-phases of the cell cycle. DNA damage-induced hyperphosphorylation of RPA2 is associated with cell-cycle arrest, decreased RPA involvement in replication and subsequent DNA repair (3) . The primary function of RPA3 is to facilitate formation of a stable RPA complex (4) .
Since RPA is involved in almost all DNA metabolic processes, it could play an important role in the pathogenesis of human malignancies, because defects in these processes may lead to gene mutations, chromosome mismatches and genomic instability, leading to cancer development and progression. In addition, RPA is required for active DNA replication, which occurs in rapidly growing tumor cells. RPA was previously reported to be aberrantly regulated in various tumors, including breast (5), colon (6) , urothelial bladder (7), astrocytic (8) and esophageal cancers (9) . Furthermore, RPA has also been identified as a potential prognostic indicator in patients with colon cancer (6) , astrocytic tumors (8) and bladder urothelial carcinoma (7) . These data suggested the value of RPA as a therapeutic target, and RPA inhibitors have been identified for potential therapeutic development (10, 11) . Although univariate survival analysis showed that both RPA1 and RPA2 were significant predictors of adverse outcome in patients with astrocytic tumors, only RPA2 remained significant in univariate analysis of grade IV tumors as well as in multivariate survival analysis of the entire cohort and for grade IV tumors (8) . In addition, a previous study demonstrated that the presence of RPA2 antibodies was a useful molecular marker for early diagnosis of breast cancer (5) .
The nuclear factor-κB (NF-κB) family of transcription factors modulates inflammation, proliferation and apoptosis (12) and is comprised of five major proteins: p50, p65 (RelA), c-rel, p52 and RelB (13) . The most abundant form of NF-κB is a cytosolic heterodimer composed of p50 and p65 that is complexed with the inhibitory protein of IκB. Specific stimulatory signals induce the phosphorylation and degradation of IκB. The p50/p65 dimer then translocates into the nucleus, where both p50 and p65 bind their cognate DNA sequences (13) . The p65 subunit is responsible for transcriptional activity, resulting in the expression of NF-κB-responsive target genes. Dysregulation of the NF-κB signaling pathway in a number of tumor cells suggested that NF-κB plays a key role in tumorigenesis (14) . A number of tumors cells, including breast cancer cells, exhibit constitutive activation of NF-κB (15) , and NF-κB activation is thought to be essential during distinct stages of breast tumor progression (16, 17) . A recent study using a transgenic model reported that inhibition of NF-κB activity in mammary epithelium resulted in increased tumor latency and a decreased tumor burden (18) .
Our present study showed that RPA2 expression was upregulated in breast cancer cells and tissues, and provided evidence that RPA2 induced a more aggressive phenotype in breast cancer cell lines. We further showed that (i) RPA2 was induced by NF-κB stimulators via an E2F1-dependent mechanism; and (ii) RPA2 activated the NF-κB signaling by interfering with the menin-NF-κB complex in breast cancer cells.
Materials and methods

Cell cultures, chemicals and antibodies, western blot, co-immunoprecipitation, QRT-PCR and ChIP assay
All cell lines (MCF-10A, HS-578T, MCF7, MDA-MB-231, T47D, ZR-75-1 and 293T) used in this study were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) in 2013. The detail information were provided in the Supplementary Data section (available at Carcinogenesis Online). MCF7 and MDA-MB-231 cells have been tested and authenticated by analyzing short tandem repeat (STR; Mission Biotech) in 2016.
Chemicals, antibodies, western blot, co-immunoprecipitation, quantitative real-time RT-PCR and chromatin immunoprecipitation (ChIP) assay, the detail information were provided in the Supplementary Data section (available at Carcinogenesis Online).
Patients, tissue samples and in silico survival assay
This study was approved by the Institutional Review Boards of National Cheng Kung University Hospital, Tainan, Taiwan. A total of 25 paired tissue samples (tumor and adjacent normal tissue) were collected from breast cancer diagnosed. Patients, tissue samples and in silico survival assay, the detail information were provided in the Supplementary data section (available at Carcinogenesis Online). All included patients were diagnosed and/or treated at the National Cheng Kung University Hospital between 2008 and 2013.
Tissue arrays and immunohistochemistry analysis
Tissue arrays CBB (Breast cancer-normal) and CBA (Breast cancer-metastasis-normal) were obtained from SuperBiochip (Seoul). Tissue array BRM961 was purchased from US Biomax (US Biomax Inc., Rockville, MD). For immunohistochemistry (IHC) assays and scoring methods were provided in the Supplementary Data section (available at Carcinogenesis Online).
Plasmids construction, transfection and established stable cell lines
Plasmids and stable cell lines used in this study, experimental details were provided in the Supplementary Data section (available at Carcinogenesis Online).
In vitro tumorigenesis assays
In vitro tumorigenesis assays include adhesion, migration and invasion analysis. Experimental details were provided in the Supplementary Data section (available at Carcinogenesis Online).
Transfection of small interfering RNA
Small interfering RNA (siRNA) duplexes specific for RPA2, p65 or E2F1 were carried out using Lipofectamine RNAiMAX reagent (Invitrogen) following manufacturer's instructions. Experimental details were provided in the Supplementary Data section (available at Carcinogenesis Online).
Luciferase assay for NF-κB activity
To analyze the NF-κB activity, the luciferase reporter plasmids was used. Experimental details were provided in the Supplementary Data section (available at Carcinogenesis Online).
Cell proliferation, clonogenic and apoptosis assay
Cell proliferation was analyzed by MTT or cell counting method. For clonogenic assay and apoptosis assay, experimental information was provided in the Supplementary Data section (available at Carcinogenesis Online).
Statistical analysis
Data were analyzed by t-tests using SigmaPlot statistical software (Systat, San Jose, CA) to determine the P values. P values less than 0.05 were considered statistically significant.
Results
Elevated expression of RPA2 in human breast cancer tissues and cell lines
We investigated the role of RPA2 in breast cancer progression by analyzing the Oncomine breast cancer gene expression database, which includes normal as well as breast cancer samples. Our analysis showed that compared to adjacent nontumor tissues, RPA2 mRNA levels were increased in primary breast cancers ( Figure 1A ) as well as in invasive breast cancers ( Figure 1B ). 
Abbreviations
Overexpression of RPA2 expression promotes cell growth, migration and invasion
In order to evaluate the functional role of RPA2 in tumor progression, RPA2 was ectopically expressed in MCF7 and MDA-MB-231 cells. Clones expressing high levels of ectopic RPA2 were pooled to form the stable RPA2-expressing MCF7 and RPA2-expressing MDA-MB-231 cell lines. Western blot analysis was used to confirm upregulation of RPA2 expression in these cell lines compared to mock-transfected cells (Figure 2A ). RPA2-expressing MCF7 cells exhibited a dis-cohesive growth pattern and a spindle-shaped fibroblastic morphology, which was not observed in its mocktransfected cells (Figure 2A , right panel). There was a significant increase in cell proliferation in RPA2-expressing MCF7 as well as RPA2-expressing MDA-MB-231 cells compared with their mocktransfected counterparts ( Figure 2B ). In addition, in vitro tumorigenesis assays revealed that both RPA2-expressing MCF7 and RPA2-expressing MDA-MB-231 cells had significantly enhanced adhesion, migration and invasion compared with their controls (Figure 2C-E) . Consistent with the EMT-like morphologic change, RPA2-expressing MCF7 cells exhibited a decrease in the epithelial marker, E-cadherin, and an increase in the mesenchymal marker, vimentin ( Figure 2F , left panel). These results suggested that ectopic RPA2 expression in MCF7 and MDA-MB-231 cells increased their malignancies, indicating that RPA2 could play a role in oncogenesis of breast cancer.
Ablation of RPA2 induce apoptosis and suppresses tumor progression
We examined whether knockdown of endogenous RPA2 protein in MDA-MB-231 cells decreased the malignancy of this cell line. The stable MDA/shRPA2 clone exhibited efficient depletion of RPA2 and western blot analysis confirmed downregulation of RPA2 expression in MDA/shRPA2 cells compared to control cells ( Figure 3A ). There was a dramatic reduction in colony formation of MDA/shRPA2 cells ( Figure 3B ). In vitro tumorigenesis assays also revealed that MDA/shRPA2 cells had significantly decreased adhesion, migration and invasion compared to control cells ( Figure 3C ). Annexin V-FITC assays showed that MDA/shRPA2 had a significantly higher apoptotic rate compared to control cells ( Figure 3D ). Furthermore, MDA/shRPA2 cells 
RPA2 inhibits the association of menin and NF-κB p65 by competitive interaction with menin
To understand the mechanism underlying RPA2-mediated oncogenesis, we used full-length RPA2 as the bait in yeast two-hybrid system in order to isolate RPA2-interacting proteins. Among the positive clones screened from a human cDNA library, two positive clones had high sequence similarity with menin, the product of the MEN1 tumor suppressor gene whose mutation causes the MEN1 syndrome. Based on a previous study which reported that RPA2 interacted with menin in HeLa cells (19) , we investigated whether RPA2 interacted with menin in breast cancer cells. Co-immunoprecipitation (co-IP) assays using MCF7 cells and MDA-MB-231 cells transfected with a Myc-MEN1 vector revealed that endogenous RPA2 was specifically co-immunoprecipitated by an anti-c-myc antibody but not by preimmune sera in both MCF7 cells and MDA-MB-231 cells (Supplementary Figure 2A , available at Carcinogenesis Online). Previous studies indicated that RPA2 and menin localized in the nucleus as well as the cytoplasm in various cell lines (20, 21) . Our data were consistent with these studies and showed that RPA2 and menin were localized both in the nucleus and the cytoplasm in MCF7 cells. However, RPA2 only interacted with menin in the nucleus (Supplementary Figure 2B , available at Carcinogenesis Online).
Menin has been shown to bind the free form of RPA2 via its amino acids 286-448 (19) , and to the NF-κB p65 subunit via amino acids 305-381 (22) . It is therefore possible that dysregulation of RPA2 expression could affect the formation of the meninp65 complex in breast cancer cells. To test this, MCF7 cells were co-transfected using Myc-MEN1 and HA-p65 along with various amounts of Flag-RPA2 plasmids. Menin was present in both Flag and HA antibody immunoprecipitates ( Figure 4A, left panel) . Western blot analysis of total cell lysates showed an increase in RPA2 expression which was proportional to the amount of transfected DNA, whereas menin and p65 levels were consistent regardless of RPA2 expression levels ( Figure 4A, right panel) . Immunoprecipitation of p65 using anti-Myc antibodies showed a decrease in co-precipitated menin which was proportional to the increase of co-precipitated RPA2 ( Figure 4A, left panel) . However, when cells were co-transfected with a C-terminal fragment of RPA2 (amino acids 172 to 271) representing a truncated form of RPA2 lacking the menin-binding region (19) , there was no significant change in the menin-p65 interaction compared to full-length RPA2 ( Figure 4B ). These results indicated that exogenous expression of full-length RPA2, but not truncated RPA2 lacking the menin-binding domain, inhibited the menin-p65 interaction. In addition, the effect of RPA2 expression levels on the menin-p65 complex formation was observed in RPA2-expressing MDA-MB-231 cells ( Figure 4C ) and in RPA2 knockdown cells, MDA/shRPA2 ( Figure 4D ). Although neither the ectopic expression nor the knockdown of RPA2 had any effect on the expression levels of menin ( Figure 4C and D) , ectopic expression of RPA2 significantly decreased, whereas knockdown of RPA2 markedly increased the formation of menin-p65 complex in RPA2-expressing MDA-MB-231 and MDA/shRPA2 cells, respectively. Our data suggested that RPA2 competes with NF-κB p65 for interaction with menin.
RPA2 can potently enhance NF-κB activity by associating with menin
Menin has been shown to exert its tumor suppression function by interacting with and repressing NF-κB-mediated transcriptional activation (22) . Based on our data showing that RPA2 could compete with NF-κB p65 for interaction with menin, we investigated whether the oncogenic function of RPA2 was associated with activation of the NF-κB p65 transcription function. To determine this, RPA2 was co-expressed with an NF-κB-responsive promoter reporter construct in order to evaluate the transactivation activity of NF-κB. RPA2 expression robustly increased NK-κB-driven luciferase activity in 293T cells ( Figure 5A ). To further substantiate our finding that RPA2 enhanced NF-κB transactivation activity, the mRNA levels of NF-κB-regulated genes were determined after RPA2 overexpression. Quantitative real-time PCR (Q-PCR) revealed that the mRNA levels of cyclin D1 (cell proliferation), c-myc (cell transformation), BCL2 (apoptosis), snail and vimentin (EMT), MMP2, MMP3 and MMP9 (invasion) were significantly upregulated in RPA2-expressing MDA-MB-231 cells (Supplementary Figure 3 , available at Carcinogenesis Online). This was confirmed on protein levels by western blot analysis ( Figure 5B ). In line with these findings, knockdown of p65 by its siRNA reduced RPA2-mediated the upregulations of NF-κB-regulated genes in RPA2-expressing MDA-MB-231 cells ( Figure 5B ). To further confirm the role of menin in RPA2-enhanced NF-κB activity, a stable Tet-On system was established for doxycycline-dependent expression of menin in RPA2-expressing MDA-MB-231 cells (23) . Expression levels of cyclin D1, c-myc, BCL2, snail, vimentin, MMP2, MMP3 and MMP9, which were elevated by overexpressing RPA2 in RPA2-expressing MDA-MB-231/Tet-on-menin cells (clone-1 and -2), were significantly decreased when expression of menin was induced ( Figure 5C ). Taken together, these data demonstrated that the oncogenic function of RPA2 was, at least in part, mediated by relieving the antagonistic function of menin on NF-κB-mediated transactivation.
RPA2 expression is upregulated by NF-κB activators via an E2F1-dependent pathway
A number of extracellular signals, including the pro-inflammatory cytokine TNF-alpha and lipopolysaccharide (LPS), the ligand of Toll-like receptor (TLR4), have been shown to activate NF-κB. We investigated whether RPA2 was involved in TNF-alpha-or LPS-induced activation of NF-κB in MCF7 and MDA-MB-231 cells. TNF-alpha-and LPS-treated MDA-MB-231 cells exhibited a significant increase in RPA2 protein levels, but not menin protein levels compared to untreated cells ( Figure 6A ). Similar results were observed in TNF-alpha-or LPS-treated MCF7 cells (data not shown). Interestingly, we showed a significant increase in the amount of RPA2 co-precipitated with menin in TNF-alphaand in LPS-treated MDA-MB-231 cells ( Figure 6A ). These results suggested that RPA2 expression in both MDA-MB-231 and MCF7 cells was upregulated in response to either TNF-alpha or LPS stimulation, which subsequently increased RPA2-menin interaction and blocked the p65-menin interaction via a competitive binding mechanism. Formation of the menin-p65 complex which was blocked by stimulation of cells with TNF-alpha or LPS, could be rescued by downregulating of RPA2 using siRNA ( Figure 6B ). These data suggested that TNF-alpha or LPS stimulation enhanced NF-κB activity and this was in part mediated by inhibition of menin-p65 complex formation via upregulation of RPA2 expression.
Consistent with what was previously reported that RPA2 expression can be induced directly via E2F1 binding sites on the RPA2 promoter (24) , in this study, the direct binding of E2F1 to PCR with primer sets 1 (the -320/-110 fragment of RPA2 promoter) was demonstrated by ChIP assay. Furthermore, the binding of them was significantly increased when cells treated with LPS and obviously reduced when cells treated with E2F1-specific siRNA ( Figure 6C, left panel) . As controls, no signals were detected with unspecific antibody (IgG) or by PCR with primer sets 2 (a genomic DNA fragment without E2F1 binding sites), which further demonstrate that the binding was site specific. In addition, we further investigated the role of E2F1 in TNFalpha-and LPS-induced RPA2 expression. TNF-alpha or LPS stimulation of MDA-MB-231 cells resulted in elevation of E2F1 as well as RPA2 protein levels, whereas expressions of menin and RPA1 appeared unchanged. Moreover, knockdown of E2F1 in MDA-MB-231 cells treated with E2F1-specific siRNA resulted in suppression of RPA2 upregulation stimulated by either TNFalpha or LPS ( Figure 6D ). These results indicated that NF-κB activators such as TNF-alpha or LPS induced RPA2 upregulation via an E2F1-dependent mechanism.
Discussion
Although previous studies have shown that overexpressing of RPA2 was detected in various cancers, studies on the role of RPA2 in the pathogenesis of cancer are very limited. In the present study, we found that RPA2, but not RPA1, was upregulated in breast cancer tissues. Survival analysis also revealed that high RPA2 expression was associated with significantly Cell lysates were subjected to luciferase assay and western blot. The luciferase activity (upper panel) observed with transfection of 2 μg of pcDNA3.1B was set as 100%.
MEN1-mediated inhibition of NF-κB activity was attenuated by RPA2. *P < 0.05; ***P < 0.001. The expression levels of NF-κB, Flag-RPA2 and Myc-MEN1 in total cell lysates were determined by western blot, indicating that an increase in RPA2 expression which was proportional to the amount of transfected DNA, whereas endogenous p65 levels were consistent regardless of RPA2 expression levels (down panel). increased risk for overall survival of breast cancer patients. In addition, expression of RPA2 protein was low in normal breast cells, higher in noninvasive and primary breast cell lines and highest in invasive TNBC cells. Ectopic expression of RPA2 in MCF7 and MDA-MB-231 cells promoted breast cancer progression, which was associated with enhanced cell proliferation, adhesion, migration and invasion. RPA2 overexpression also induced EMT of MCF7 cells, whereas downregulation of RPA2 in MDA-MB-231 cells led to suppression of EMT, suppression of invasion and induction of apoptosis. Our results provide strong evidence that RPA2 overexpression plays an important role in promoting the tumorigenicity and progression of human breast cancer.
Menin is a nuclear protein encoded by the MEN1 tumor suppressor gene which is disrupted in multiple Type 1 endocrine neoplasias. Menin is expressed in almost all normal tissues and plays a critical role in many cellular processes, including transcriptional regulation, apoptosis, DNA repair and genome stability (25) . Multiple lines of evidence indicate that menin acts as a tumor suppressor in several types of tumors (26) . MEN1 has also been implicated in the progression of breast cancer (27) . Disruption of MEN1 was recently shown to play a role in the predisposition of mice to precancerous mammary lesions (28) . The increased risk of breast cancer in female patients with MEN1 mutations further supported the role of menin as a tumor suppressor (29) . Our present data, which showed that RPA2 physically interacts with menin in the nucleus of breast cancer cells, were consistent with a previous report (19) . Our study provided compelling evidence that the interaction of RPA2 with menin could block menin-NF-κB coupling via a competitive binding mechanism. First, exogenous expression with RPA2, but not the truncated form of RPA2 which lacked the menin-binding domain, inhibited the menin-p65 interaction. Second, the formation of the menin-p65 complex was significantly decreased in cells overexpressing RPA2 and significantly increased after knockdown of RPA2. Although different domains of menin are required for RPA2 and NF-κB binding, it is possible that conformational changes after binding of menin to RPA2 or NF-κB may hinder the binding region for RPA2 or NF-κB. Accordingly, we found that ectopically expressed RPA2 competitively interfered with the menin-NF-κB interaction, and depletion of RPA2 increased menin-NF-κB complex formation. Our data also hours) or LPS (1 µg/ml, 24 hours), subjected to co-immunoprecipitation with IgG only (mock control) or an anti-RPA2 antibody and then immunoblotted using the MEN1 antibody. The results indicated that RPA2 expression was upregulated (5% input) and RPA2-MEN1 complex was increased after TNF-alpha or LPS treatment. (B) MDA-MB-231 cells were treated with mock or RPA2 siRNA for 48 hours. Cells were then treated with LPS (1 µg/ml for 24 hours) or TNF (10 ng/ml for 2 hours) and subjected to co-immunoprecipitation assays with IgG only (mock control) or an anti-p65 antibody. Samples were immunoblotted using an MEN1 antibody. (C) E2F1 binds to RPA2 promoter region using ChIP assay. After E2F1 specific siRNA or scrambled siRNA treatments, MDA-MB-231 cells only or scrambled and E2F1-siRNA-treated cells were treated with or without LPS (1 µg/ml for 24 hours), then cells were subjected to ChIP analysis using E2F1 antibody. IgG was used as a unspecific control. The RPA2 promoter region containing E2F1 binding sites (from -320 to -110) and a genomic region without E2F1 binding sites (from -980 to -726) were performed by PCR using primer (1 µg/ml for 24 hours) or TNF-alpha (10 ng/ml for 2 hours) and subjected to western blot analysis using RPA2, E2F1, MEN1, RPA1 and GAPDH antibodies. Compared to mock siRNA transfected cells, neither TNF-alpha nor LPS induced RPA2 levels in E2F1 knockdown cells.
suggested that aberrant overexpression of RPA2, which was detected in some clinical breast cancers, could confer a similar effect by inhibiting the menin-NF-κB p65 interaction.
Activation of NF-κB and the subsequent induction of its target genes lead to the oncogenesis in mammalian cells. Previous studies reported the detection of elevated or constitutive NF-κB activity in most human breast cancer cells (30) , suggesting that NF-κB plays a major role in the pathogenesis of breast cancer. In addition, NF-κB has also been identified as a central mediator of EMT in a mouse model of breast cancer progression (17) . However, the mechanisms underlying the activation of NF-κB signaling pathways during the initiation and progression of breast cancer remain poorly understood. In this study, we used luciferase reporter assays and analyzed NF-κB downstream gene expression to demonstrate that interaction of RPA2 with menin is crucial for activation of the NF-κB signaling pathway. Activation of NF-κB has been shown to induce a number of genes involved in cell proliferation (cyclin D1), transformation (c-myc), cell survival (anti-apoptotic factor, BCL2), EMT (snail, vimentin) and invasion (MMP2, MMP3, MMP9) (31) . Importantly, NF-κB has been linked to mammary cancer-initiating cells (CICs) (32) . It has also been documented that NF-κB activation promotes cell migration and invasion by stabilization of snail in breast cancer cells (33) . In addition, MMP3-induced ROS was recently shown to stimulate EMT in mammary epithelial cells via NF-κB-dependent activation of snail (34) . Our data were consistent with these studies and showed that RPA2 enhanced NF-κB activity in RPA2-overexpressing MDA-MB-231 cells, resulting in the induction of a number of NF-κB target genes. Conversely, knockdown of p65 by its siRNA reduced RPA2-mediated the upregulations of NF-κB-regulated genes in RPA2-expressing MDA-MB-231 cells. In addition, RPA2 upregulated the expression of NF-κB target genes by inhibiting the menin-NF-κB p65 interaction, which was confirmed after conditional induction of menin in a stable inducible MDA-MB-231 cell line. Our data also showed that RPA2 upregulation resulted in enhanced breast cancer cell proliferation, adhesion, migration and invasion as well as induced EMT, whereas ablation of RPA2 led to the opposite cell biological characteristics and induced apoptosis. Based on these results, it is intriguing to speculate that RPA2 potently promoted breast cancer initiation and progression by inhibiting the formation of the menin-NK-κB p65 complex, which resulted in NF-κB activation and consequent induction of its downstream genes such as cyclin D1, c-myc, BCL2, snail, vimentin, MMP2, MMP3 and MMP9.
The inflammatory cytokine, TNF-alpha, is highly expressed in breast carcinomas, and in vitro activation of the TNF-alpha/ NF-κB axis was shown to induce invasive and malignant behavior in breast cancer cells (35) . Based on these results, and the finding that NF-κB is the main pathway that is activated in response to LPS stimulation (36), we examined whether RPA2 is involved in TNF-alpha-and LPS-induced NF-κB activation. The present study demonstrated for the first time that (i) both TNF-alpha and LPS increased the expression of RPA2 and subsequently increased the RPA2-menin interaction; and (ii) suppression of menin-p65 complex formation by TNF-alpha or LPS stimulation could be rescued in cells expressing RPA2 shRNA. Since NF-κB transcriptional activity is required for maintenance of the invasive phenotype in cancers through the upregulation of inflammatory cytokines (37) , our data suggested that upregulation of RPA2 may be involved in the acceleration of NF-κB activation by TNF-alpha and LPS.
E2F1 has been shown to possess oncogenic properties and there is strong evidence to show that regulation of E2F1 activity plays a key role in tumorigenesis (38) . In addition, a previous study reported that expression of RPA2, but not RPA1 or RPA3, could be profoundly induced by E2F1 in various cell lines including MCF7 and H1299 cells (28) . Given this background, we examined whether E2F1 was involved in TNF-alpha-and LPS-induced RPA2 expression. We showed that exposure to TNF-alpha or LPS led to upregulation of RPA2 and E2F1 in MCF7 as well as MDA-MB-231 cells. Moreover, TNF-alpha-or LPSinduced RPA2 expression was inhibited in MDA-MB-231 cells where E2F1 expression was knocked down with E2F1-specific siRNA. Our data indicated that induction of RPA2 expression by TNF-alpha and LPS was mediated by the transcription factor E2F1. It has been reported that TNF-alpha could increase the expression of E2F1-regulated genes such as proliferative cdc6, thymidylate synthase (TS) and cdc5 in aortic smooth muscle cells (AoSMC) (39) . In addition, E2F1 has been identified as a transcriptional activator recruited by NF-κB upon TLR4 activation in an LPS-stimulated human monocytic cell line (40) , and in vivo murine knockout data confirmed that mice deficient in E2F1 had a reduced inflammatory response to systemic LPS (41). Our study indicated that TNF-alpha or LPS stimulation resulted in an increase in the total amount of E2F1 in breast cancer cells, which is consistent with the previously mentioned studies. Furthermore, we also showed that overexpression of RPA2 blocked the formation of the menin-NF-κB p65 complex, allowing NF-κB to transcriptionally activate its gene targets. On the basis of these findings, the fact that menin is ubiquitously expressed in many cultured cells and various tissues (42) and the fact that menin has been shown to be a tumor suppressor in breast cancer (28), we suggest that RPA2 overexpression contributed to NF-κB activation also in the absence of cytokine stimulation. Our hypothesis is that RPA2 upregulation may occur during tumor development through currently unidentified mechanisms. Once a significant level of RPA2 expression is achieved which can compete with NF-κB for interaction with menin, activation of the NF-κB pathway could be self-sustained in the absence of external inflammatory stimuli. In addition, production of cytokines such as TNF-alpha by cancer cells or when cells encounter life-threatening infections, NF-κB activation achieved by the TNF-alpha or LPS /E2F1 /RPA2/ NF-κB pathways, results in sustained activation of NF-κB and greater responsiveness to pro-inflammatory signals, thereby constituting a loop of signal amplification for acceleration of breast cancer progression.
A functional RPA protein contains three subunits, all of which are essential for DNA replication, cell viability and chromosome stability (1) . Thus, biosynthesis of all three subunit is thought to be strictly coordinated with the changes in cellular growth in normal cells. However, it has been reported that although the large majority of three RPA subunits is present in the intact RPA complex, low levels of non-heterotrimeric RPA2 are present in HeLa cells and 293 cells (43, 44) . In addition, although RPA1 in the absence of RPA2 is quickly degraded in vivo, RPA2 free of RPA1 can be detected in RPA1 siRNA-treated HeLa cells (45) . These findings implied that, in addition to playing a role in assembling a functional RPA complex, the free form of RPA2 might act as an independent unit involved in other cellular functions. This notion was supported by the observations that the free form of RPA2 interacted with a number of other cellular proteins such as STAT3 (46) , RBT1 (47) and 4E-BP3 (48) . It has been proposed that RPA2 overexpression may inactivate p53, thus allowing cells with DNA damage to proceed through the cell cycle MDA-MB-231. In addition, under some conditions, expression of RPA2, but not RPA1 or RPA3, could be profoundly induced by E2F1 in various cell lines as aforementioned. Elevated protein levels of RPA2 were also more frequently observed in BRCA breast tumors (49) . Recently, RPA2 expression was reported to be translationally regulated via the internal ribosome entry site (IRES) and by eIF3a, the largest subunit of eIF3, whose expression has been associated with tumorigenesis and malignant transformation, metastasis and cancer prognosis (50) . Here, we provide evidence for the oncogenic properties of RPA2, independent of its role for DNA replication. We also provide evidence linking inflammation, NF-κB activation and breast cancer progression. Our data suggested that upregulation of RPA2 might be an important mechanism to maintain constitutive NF-κB activation. However, although our data indicated that menin and NF-κB are the major targets of RPA2 in breast cancer, we cannot exclude the probability that RPA2 could target other oncogenes and/or tumor suppressors besides menin and NF-κB in breast cancer cells. It is important to perform high-throughput screening to identify RPA2 targets in various human cancers to better understand the mechanisms of RPA2 in tumor development.
In summary, this study demonstrated that overexpression of RPA2 promoted oncogenic properties and RPA2 physically interacted with menin. Overexpression of RPA2 in tumor cells activated NF-κB by relieving the antagonistic function of menin on NF-κB-mediated transcription in breast cancer cells, resulting in elevated levels of numerous oncoproteins downstream of NF-κB. RPA2 expression is enhanced by various stimuli including TNF-alpha and LPS, suggesting that it may be implicated in a flexible inflammatory response to diverse stimuli and biological situations. Targeting the RPA2-menin interaction or suppressing the oncogenic functions of RPA2 can be an effective and novel therapeutic approach for breast cancer.
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